S. Korea Newspaper Says Pfizer Korea Not Candid About Champix Effects
This article was originally published in PharmAsia News
Executive SummaryPfizer Korea has been accused in a newspaper report of being less than candid about the side effects of its Champix (varenicline) anti-smoking drug. The Korea Times quoted Pfizer Korea as saying it reported all side effects to Korea FDA, but would not say what they were. The newspaper cited various conclusions by government authorities critical of the drug, some saying that although it is approved for eliminating the curb the desire to smoke, it is implicated in suicides and other deaths after use. (Click here for more
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.